Overview

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Status:
Not yet recruiting

Trial end date:
2023-04-30

Target enrollment:

Participant gender:

Summary

Cohort 1: Main research purpose: To evaluate the effectiveness of fluzoparib single-drug comparison researcher's choice of chemotherapy for patients with metastatic castration-resistant prostate cancer; Cohort 2, cohort 3: Main research purpose: To evaluate the effectiveness of fluzoparil combined with apatinib mesylate in the treatment of patients with metastatic castration-resistant prostate cancer;

Phase:

Phase 2

Details

Lead Sponsor:

Jiangsu HengRui Medicine Co., Ltd.

Treatments:

Abiraterone Acetate
Apatinib
Prednisone